Insight on Pharmaceutical Manufacturers

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Click here to sort results by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Alcon Inc.: PharmaVitae Profile

Analysis of Alcon's corporate strategy, marketed portfolio, pipeline potential and financial position in 2009 and to 2015

Published By Datamonitor
16 Dec 2010 $2800
Buy
Case Studies
Case Studies

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

In 2007, Alexion gained marketing approval for Soliris, which has since become the world’s single most expensive orphan drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Published By MarketLine
16 Jan 2013 $495
Buy
Report
Report

Allergan Inc.: PharmaVitae Report

Analysis of Allergan's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
09 Dec 2011 $2800
Buy
Report
Report

Apotex Inc.: PharmaVitae Report

Analysis of Apotex's corporate strategy, marketed portfolio and pipeline potential over 2010-2016.

Published By Datamonitor
21 Dec 2011 $2800
Buy
Report
Report

Astellas Pharma Inc.: PharmaVitae Report

Analysis of Astellas's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
02 Sep 2011 $2800
Buy
Report
Report

Bayer AG: Company Analysis

Analysis of Bayer's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $2800
Buy
Report
Report

Boehringer Ingelheim: Company Analysis

Analysis of Boehringer Ingelheim's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
26 Oct 2012 $2800
Buy
Report
Report

Bristol-Myers Squibb Co.: Company Analysis

Analysis of BMS's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017

Published By Datamonitor
08 Aug 2012 $2800
Buy
Report
Report

Company Analysis: Johnson & Johnson

Analysis of Johnson & Johnson's corporate strategy, marketed portfolio, pipeline potential, and financial position in 2011 and to 2017.

Published By Datamonitor
17 Dec 2012 $2800
Buy
Report
Report

Daiichi Sankyo Co., Ltd: PharmaVitae Report

Analysis of Daiichi Sankyo's corporate strategy, marketed portfolio, pipeline potential and financial position in 2010 and to 2016

Published By Datamonitor
27 Jan 2012 $2800
Buy

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.